Repositioning Candidate Details
| Candidate ID: | R0016 |
| Source ID: | DB00134 |
| Source Type: | approved; nutraceutical |
| Compound Type: | small molecule |
| Compound Name: | Methionine |
| Synonyms: | |
| Molecular Formula: | C5H11NO2S |
| SMILES: | CSCC[C@H](N)C(O)=O |
| Structure: |
|
| DrugBank Description: | A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. |
| CAS Number: | 63-68-3 |
| Molecular Weight: | 149.211 |
| DrugBank Indication: | Used for protein synthesis including the formation of SAMe, L-homocysteine, L-cysteine, taurine, and sulfate. |
| DrugBank Pharmacology: | L-Methionine is a principle supplier of sulfur which prevents disorders of the hair, skin and nails; helps lower cholesterol levels by increasing the liver's production of lecithin; reduces liver fat and protects the kidneys; a natural chelating agent for heavy metals; regulates the formation of ammonia and creates ammonia-free urine which reduces bladder irritation; influences hair follicles and promotes hair growth. L-methionine may protect against the toxic effects of hepatotoxins, such as acetaminophen. Methionine may have antioxidant activity. |
| DrugBank MoA: | The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine is a precursor to L-cysteine. L-cysteine itself may have antioxidant activity. L-cysteine is also a precursor to the antioxidant glutathione. Antioxidant activity of L-methionine and metabolites of L-methionine appear to account for its possible anti-hepatotoxic activity. Recent research suggests that methionine itself has free-radical scavenging activity by virtue of its sulfur, as well as its chelating ability. |
| Targets: | Methionine synthase reductase; Methionine synthase; Methionine aminopeptidase 2; Betaine--homocysteine S-methyltransferase 1; S-methylmethionine--homocysteine S-methyltransferase BHMT2 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |